CVRx, Inc. (CVRX)

Over the past six months, CVRx's stock price has decreased by 27.16%. Key events impacting the stock include the release of the Fourth Quarter and Full Year 2025 financial results on February 12, 2026, which showed a revenue increase. On January 1, 2026, new Category I CPT codes and favorable physician fee payment levels took effect. On April 13, 2026, preliminary first-quarter 2026 results were reported, showing a revenue increase and improved gross margin, leading to a positive market reaction. On May 4, 2026, the enrollment of the first patient in the BENEFIT-HF trial was announced, a landmark heart failure trial evaluating Barostim.

CVRx experiences demand seasonality, particularly a "typical Q1 dip" in medical device sales. This seasonality impacted the company's Q1 2025 revenue, but management views such dips as temporary.

CVRx, Inc. is a medical device company specializing in neuromodulation solutions for cardiovascular diseases. Its main product, Barostim, is an FDA-approved implantable device that uses baroreflex activation therapy to improve symptoms in heart failure patients by delivering electrical pulses to carotid baroreceptors, restoring balance to the autonomic nervous system. The company sells its products through a direct sales force, sales agents, and independent distributors.

CVRx, Inc. operates in the United States, Germany, and other international markets. As of March 31, 2026, the company had 257 active U.S. implanting centers and 56 U.S. sales territories, reflecting an expansion from 252 active implanting centers and 53 U.S. sales territories in December 2025.

CVRx's brand reputation is generally positive, supported by its innovative product Barostim and clinical advancements. Barostim has received FDA and CE Mark approvals. Analysts have given CVRx a "Moderate Buy" consensus rating, with an average 1-year price objective of $10.50. The company focuses on improving patient outcomes and cardiovascular health through baroreceptor neuromodulation therapies. A past stock drop in April 2025 due to a revenue miss and sales force realignment could have affected its reputation, but continued revenue growth and strategic initiatives demonstrate a commitment to long-term growth.

CVRx, Inc. has a mixed ownership structure including institutional, insider, and individual investors. Ownership percentages vary across different sources and dates, with institutional ownership ranging from approximately 40% to 75.27%, insider ownership ranging from under 1% to 82.97%, and retail investors holding between 0.00% and 58.26%. Major institutional owners include Johnson & Johnson, NEA Management Company, LLC, Vanguard Group Inc, and BlackRock, Inc. Johnson & Johnson is also noted as the largest individual shareholder.